Nuvalent, Inc.

Nuvalent, Inc.verified

NUVL

Price:

$103.74

Market Cap:

$7.24B

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-gener...[Read more]

Industry

Biotechnology

IPO Date

2021-07-29

Stock Exchange

NASDAQ

Ticker

NUVL

The Enterprise Value as of October 2024 (TTM) for Nuvalent, Inc. (NUVL) is 7.16B

According to Nuvalent, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 7.16B. This represents a change of 74.45% compared to the average of 4.11B of the last 4 quarters.

Nuvalent, Inc. (NUVL) Historical Enterprise Value (quarterly & annually)

How has NUVL Enterprise Value performed in the past?

The mean historical Enterprise Value of Nuvalent, Inc. over the last ten years is 1.57B. The current 7.16B Enterprise Value has changed 45.59% with respect to the historical average. Over the past ten years (40 quarters), NUVL's Enterprise Value was at its highest in in the March 2024 quarter at 4.85B. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.

Quarterly (TTM)
Annual

Average

1.57B

Median

904.48M

Minimum

851.06M

Maximum

3.95B

Nuvalent, Inc. (NUVL) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Nuvalent, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 219.17%

Maximum Annual Enterprise Value = 3.95B

Minimum Annual Increase = -5.15%

Minimum Annual Enterprise Value = 851.06M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
20233.95B219.17%
20221.24B45.39%
2021851.06M-5.15%
2020897.23M-0.80%

Nuvalent, Inc. (NUVL) Average Enterprise Value

How has NUVL Enterprise Value performed in the past?

The current Enterprise Value of Nuvalent, Inc. (NUVL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

2.01B

5-year avg

1.57B

10-year avg

1.57B

Nuvalent, Inc. (NUVL) Enterprise Value vs. Peers

How is NUVL’s Enterprise Value compared to its peers?

Nuvalent, Inc.’s Enterprise Value is less than DICE Therapeutics, Inc. (0), greater than Arcellx, Inc. (2.21B), greater than Vaxcyte, Inc. (4.26B), less than Viridian Therapeutics, Inc. (12.98B), greater than Ventyx Biosciences, Inc. (1.73B), greater than Cullinan Oncology, Inc. (121.57M), greater than Kiniksa Pharmaceuticals, Ltd. (828.67M), greater than Replimune Group, Inc. (1.64B), greater than Ascendis Pharma A/S (719.89M), less than United Therapeutics Corporation (7.60B), less than Cerevel Therapeutics Holdings, Inc. (14.87B), less than Travere Therapeutics, Inc. (8.24B), greater than Structure Therapeutics Inc. (1.48B), greater than null (2.13B),

Build a custom stock screener for Nuvalent, Inc. (NUVL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nuvalent, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Nuvalent, Inc. (NUVL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Nuvalent, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Nuvalent, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Nuvalent, Inc. (NUVL)?

What is the 3-year average Enterprise Value for Nuvalent, Inc. (NUVL)?

What is the 5-year average Enterprise Value for Nuvalent, Inc. (NUVL)?

How does the current Enterprise Value for Nuvalent, Inc. (NUVL) compare to its historical average?